MétaCan
Menu
Back to cohort
Record W4385989336 · doi:10.1016/j.annonc.2023.08.003

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

2023· article· en· W4385989336 on OpenAlexafffund
Komal Jhaveri, L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni, Adam Brufsky, H. Park, James Waisman, Eddy S. Yang, Iben Spanggaard, Sonya Reid, Mark E. Burkard, S Vinayak, Aleix Prat, Mónica Arnedos, François‐Clément Bidard, Sherene Loi, John Crown, Manali Bhave, Sarina A. Piha‐Paul, Jennifer M. Suga, Stephen Chia, Cristina Saura, José Á. García-Sáenz, Valentina Gambardella, Einav Nili Gal‐Yam, A. Raphael, Salomon M. Stemmer, X. Cynthia, Ariella B. Hanker, D. Ye, Jonathan W. Goldman, Ron Bose, Lanell M. Peterson, Joshua S. K. Bell, A. Lindsay Frazier, D. DiPrimeo, Alvin Wong, Carlos L. Arteaga, David B. Solit

Bibliographic record

VenueAnnals of Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsBC Cancer Agency
FundersNational Cancer InstitutePrincipia BiopharmaImmunoMedicsSierra OncologyLoxo OncologyChugai PharmaceuticalAstraZenecaGenentechAmgenScience Foundation IrelandSeagenG1 TherapeuticsDaiichi-SankyoMacroGenicsSilverback TherapeuticsFibroGenPuma BiotechnologyNovartis Pharmaceuticals CorporationF-star TherapeuticsAminex TherapeuticsF. Hoffmann-La RocheGenomic HealthMenarini Silicon BiosystemsBeiGeneUniversity of Wisconsin Carbone Cancer CenterSun PharmaFive Prime TherapeuticsArray BioPharmaMerck KGaAMemorial Sloan-Kettering Cancer CenterNational Institutes of HealthNateraBioMarin PharmaceuticalAstellas PharmaEisaiDaiichi Sankyo EuropeUniversity of Wisconsin-MadisonNational Breast Cancer FoundationIncyteServierGilead SciencesExelixisJounce TherapeuticsBreast Cancer Research FoundationApollomicsSanofiGlaxoSmithKlineCelgeneBristol-Myers SquibbEli Lilly and CompanyPfizer
KeywordsFulvestrantNeratinibMedicineTrastuzumabMetastatic breast cancerInternal medicineOncologyResponse Evaluation Criteria in Solid TumorsBreast cancerCancerGastroenterologyProgressive diseaseChemotherapyTamoxifen

Abstract

fetched live from OpenAlex
No abstract in any covered source. Its absence is recorded, not treated as a negative.

No abstract. This is not a gap in this database; OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0020.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.002
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.099
GPT teacher head0.420
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations61
Published2023
Admission routes2
Has abstractno

Explore more

Same venueAnnals of OncologySame topicAdvanced Breast Cancer TherapiesFrench-language works237,207